H. Lundbeck A/S: PharmaVitae Profile

Product Code DAT00432
Publication Date June 2010
Publisher Datamonitor
Product Type Report
Pages 57
ISBN Number not applicable
Change currency
PDF £3,605.00 €4,341 $5,700 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

H. Lundbeck A/S: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Lundbeck in the prescription pharma global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Key reasons to purchase this research

  • Benchmark Lundbeck's performance against key rivals in the prescription pharmaceutical sector
  • See how Lundbeck will outperform many of its CNS peers to achieve strong growth out to 2014, having struggled in recent years
  • Evaluate the long-term risks the company faces in terms of generic threat and pipeline attrition

Contents

  • EXECUTIVE SUMMARY
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2002–14
    • Financial performance, 2002–14
    • Lundbeck: PharmaVitae forecasts at a glance
    • Strategic insight
    • SWOT analysis
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
  • QUARTERLY UPDATE
    • Latest prescription pharma product news
      • Q1 2010
      • Q4 2009
      • Q3 2009
      • Q2 2009
    • Latest corporate news
      • Q4 2009
      • Q3 2009
  • COMPANY INTRODUCTION
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
    • Current corporate structure
  • COMPANY SALES
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2002–14
    • Product analysis
      • Product analysis, 2002–08
      • Product analysis, 2008–14
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
      • Explanation of launch/core/expiry analysis
      • Launch analysis, 2008–14
      • Core analysis, 2008–14
      • Expiry analysis, 2008–14
      • Launch/core/expiry configuration, 2008–14
    • Molecule type analysis
    • Externalization analysis
  • COMPANY FINANCIALS
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002–08
    • Operating costs and profit analysis
      • Operating costs and profit analysis, 2002–08
      • Operating cost ratio and profit margin analysis, 2002–08
      • Operating cost ratio and profit margin analysis, 2008–14
      • Operating costs and profit analysis, 2008–14
  • KEY PRODUCTS AND COMPETITORS
    • Overview
    • Cipralex (including Lexapro royalties)
      • Overview
      • Sales forecast
    • Ebixa
      • Overview
      • Sales forecast
  • APPENDIX
    • References
    • Abbreviations
    • Exchange rates
  • TABLES
    • Table: Lundbeck – PharmaVitae forecasts at a glance
    • Table: Lundbeck product portfolio overview ($m), 2002–08
    • Table: Lundbeck product portfolio overview ($m), 2008–14
    • Table: Lundbeck prescription pharmaceutical sales by therapy area ($m), 2008–14
    • Table: Lundbeck prescription pharmaceutical sales by geographic region ($m), 2008–14
    • Table: Lundbeck launch portfolio overview ($m), 2008–14
    • Table: Lundbeck core portfolio overview ($m), 2008–14
    • Table: Lundbeck expiry portfolio overview ($m), 2008–14
    • Table: Lundbeck prescription pharmaceutical sales by molecule type ($m), 2008–14
    • Table: Lundbeck prescription pharmaceutical sales by source ($m), 2008–14
    • Table: Total Lundbeck sales by business unit ($m), 2002–08
    • Table: Lundbeck operating revenue/cost analysis ($m), 2002–08
    • Table: Lundbeck operating cost ratio analysis (% of total revenues), 2002–08
    • Table: Lundbeck operating cost ratio analysis (% of total revenues), 2008–14
    • Table: Lundbeck operating revenue/cost analysis ($m), 2008–14
    • Table: Key products overview
    • Table: Cipralex: overview
    • Table: Cipralex: sales forecast ($m), 2008–14
    • Table: Ebixa: overview
    • Table: Ebixa: sales forecast ($m), 2008–14
    • Table: Exchange rates, 2009
  • FIGURES
    • Figure: The PharmaVitae Explorer
    • Figure: Lundbeck prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002–14
    • Figure: Lundbeck’s financial performance ($m), 2002–14
    • Figure: Share of CNS market in 5EU and ‘rest of world’ by company (%), 2008–14
    • Figure: Lundbeck SWOT analysis
    • Figure: Lundbeck prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002–14
    • Figure: Key product sales ($m), 2002–14
    • Figure: Lundbeck key sales growth drivers and resistors ($m), 2002–08
    • Figure: Lundbeck key sales growth drivers and resistors ($m), 2008–14
    • Figure: Lundbeck prescription pharmaceutical sales by therapy area ($m), 2002–14
    • Figure: Lundbeck prescription pharmaceutical sales by geographic region ($m), 2002–14
    • Figure: Lundbeck launch/core/expiry configuration ($m), 2008–14
    • Figure: Lundbeck prescription pharmaceutical sales by molecule type ($m), 2002–14
    • Figure: Lundbeck prescription pharmaceutical sales by source ($m), 2002–14
    • Figure: Lundbeck operating revenue/cost analysis ($m), 2002–14
    •